TL‐1A belongs to the TNF superfamily of ligands. It is expressed predominantly in endothelial cells, and to a lesser extent in the placenta, lung, kidney, skeletal muscle, pancreas, small intestine and colon. TL‐1A inhibits endothelial cell proliferation and angiogenesis, and has been shown to induce NF‐κB activation, caspase activity, and apoptosis in responding cell lines. TL‐1A interacts with TNFRSF25/DR3 receptor, but can also bind to a decoy receptor TNFRSF21/DR6. Recombinant Human TL‐1A is a 22.1 kDa polypeptide of 195 amino acid residues.
Manufactured using all Animal-Free reagents.
MQLRAQGEAS VQFQALKGQE FAPSHQQVYA PLRADGDKPR AHLTVVRQTP TQHFKNQFPA LHWEHELGLA FTKNRMNYTN KFLLIPESGD YFIYSQVTFR GMTSECSEIR QAGRPNKPDS ITVVITKVTD SYPEPTQLLM GTKSVCEVGS NWFQPIYLGA MFSLQEGDKL MVNVSDISLV DYTKEDKTFF GAFLL
≥ 98% by SDS-PAGE gel and HPLC analyses.
Determined by its ability to stimulate IFN-γ production by human PBMC co-stimulated with Human IL-12 and Human IL-18.
Calculated Molecular Weight:
Endotoxin level is < 0.01 ng/ug of protein (< 0.1 EU/ug)
Not for human use.